Despite having suffered clinical failures with Lupuzor (forigerimod), and considerable concerns from the investment community about the drug's prospects, the UK's ImmuPharma PLC is still convinced that it still has a potential blockbuster for lupus on its hands.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?